

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai MicroPort MedBot (Group) Co., Ltd.**

**上海微创医疗机器人(集团)股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2252)**

### **VOLUNTARY ANNOUNCEMENT**

## **R-ONE VASCULAR INTERVENTIONAL SURGICAL ROBOT OBTAINED APPROVAL FOR MARKETING FROM THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA**

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company is pleased to announce that the R-ONE Vascular Interventional Surgical Robot (“**R-ONE**”) introduced by the Cathbot (Shanghai) Robot Co., Ltd., a joint venture company in China jointly established by the Company and Robocath S.A.S in France, has obtained the approval for marketing from the National Medical Products Administration of China (“**NMPA**”).

### **ABOUT R-ONE**

R-ONE is a vascular intervention control system based on master-slave control technologies, which is designed to assist cardiovascular interventional physicians in conducting percutaneous coronary intervention (“**PCI**”) surgeries to locate lesions precisely, optimize the delivery of balloons and stent catheters, therefore standardizing surgical procedures, improving the surgical accuracy and reducing surgical complications. In addition, by using R-ONE, surgeons can be seated behind the radiation-proof control panel to operate remotely, which can effectively reduce the exposure time under radiation while achieving precise surgical operations.

## **IMPACT ON THE COMPANY**

As the first commercialised coronary vascular interventional robot that has completed multi-center clinical trials and been approved in China, R-ONE is expected to fill the gap in the field of PCI surgical robots in China, which will not only provide good clinical experience to physicians, but also allow patients to receive more accurate, safer and more effective treatments, and promote the realization of the integrated solution of future intelligent catheterization room for coronary intervention, thus continuously fulfilling the belief of “make surgery easier, safer, and less invasive”.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in shares of the Company.**

By order of the Board  
**Shanghai MicroPort MedBot (Group) Co., Ltd.**  
**Mr. Sun Hongbin**  
*Chairman*

Shanghai, China, 13 December 2023

*As at the date of this announcement, the executive director of the Company is Dr. He Chao, the non-executive directors of the Company are Mr. Sun Hongbin, Mr. Sun Xin and Mr. Chen Chen, and the independent non-executive directors of the Company are Dr. Li Minghua, Mr. Yao Haisong and Mr. Mui Wing Hong.*